UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its holdings in Mind Medicine (MindMed) Inc.

Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) has earned an average recommendation of “Buy” from the eleven research firms that are covering the firm, MarketBeat.com reports.

Fintel reports that on December 20, 2024, Chardan Capital initiated coverage of Mind Medicine (NasdaqGS:MNMD) with a Buy ...

Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23.

Mind Medicine (MNMD) or MindMed announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically ...

NEW YORK, December 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...

NEW YORK, December 11, 2024--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain ...

纽约 - 专注于开发脑健康疾病治疗方法的生物制药公司Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)被选入纳斯达克生物技术指数 (NBI)。该公司将于2024年12月23日开盘时正式纳入指数。目前，该公司市值约5.3亿美元，根据 InvestingPro 分析，其财务健康状况获得FAIR评级。

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel ...

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders ...